23 related results for Dabigatran

NOACs confer lower bleeding risk than VKA in low-risk AF patients

Literature 21-6-2017 • Lip GYH et al., JAMA Cardiol. 2017
In AF patients with a single non-gender-related stroke risk factor, the risk of any bleeding was lower for apixaban and dabigatran compared with warfarin, while no difference in stroke prevention was seen.

FORTA classifies all DOACs and warfarin as beneficial for older AF patients

Literature 17-5-2017 • Wehling M, et al, Drugs & Aging 2017
Based on FORTA classification, all DOACs and warfarin were classified as beneficial or very beneficial for older AF patients, while there was lack of evidence for other vitamin K antagonists.

Doubled risk of acute MI in real world AF patients receiving DOACs or aspirin vs. VKA

Literature 11-4-2017 • Stolk LM et al., Br J Clin P harmacol 2017
Analysis of new users of rivaroxaban or dabigatran, aspirin and VKAs in CPRD reveals a two-fold increased risk of AMI in current users of DOAC or aspirin, as compared with VKA.

Undercoagulation was common in AF patients who suffered from stroke and impacts outcome

Literature 5-4-2017 • Xian Y et L., JAMA. 2017
In a contemporary registry, 84% of patients with a history of AF received no or subtherapeutic anticoagulation, which affected severity of stroke and in-hospital mortality.

Gastrointestinal safety profiles differ among direct oral anticoagulants

Literature 28-3-2017 • Abraham NS, et al, Gastroenterology 2017
In a large population-based cohort of AF patients on DOACs, apixaban had most favourable gastrointestinal safety profile among all age groups, and rivaroxaban the least favourable. 

Reduced doses NOAC show similar efficacy and bleeding risk but possibly higher mortality risk

Literature 20-2-2017 • Nielsen PB et al., BMJ. 2017
Real-world data show lower dose NOACs associated with similar risk of thromboembolic events and similar or lower rates of bleeding as compared with warfarin in AF, but mortality risk seems higher with NOACs.

Lower risk of liver injury hospitalisation with DOACs as compared to warfarin

Literature 10-1-2017 • Alonso A et al., Heart. 2017
Dabigatran, rivaroxaban and apixaban users were less often associated with liver injury hospitalisation compared to warfarin and several variables could predict this.

DOACs also beneficial for elderly AF and VTE patients

Literature 11-10-2016 • Sadlon AH, Swiss Med Wkly, 2016
Rivaroxaban, apixaban, dabigatran and edoxaban were superior to VKAs in a meta-analysis of 8 studies comprising elderly patients with atrial fibrillation or venous thromboembolism.

Real-world safety data show differences between anticoagulants in AF patients

Literature 23-8-2016 • Lip GYH et al., Thromb Haemost 2016
In a real-world observational study using propensity score matched cohorts, apixaban initiation was associated with significantly lower risk of major bleeding compared to warfarin and rivaroxaban.

EHRA practical guide for non-vitamin K antagonist anticoagulants in non-valvular AF patients updated

News 15-6-2016
The European Heart Rhythm Association (EHRA) published a rewritten, updated version of the previously published (2013) guidelines for NOACs in non-valvular AF patients.

Direct oral anticoagulants result in lower risk of dementia in atrial fibrillation patients

Literature 9-6-2016 • Jacobs V, et al. Am J Cardiol. 2016
Treatment with direct oral anticoagulants was associated with a lower risk of cerebral ischemic events and new-onset dementia, in a retrospective analysis of 5,254 patients with atrial fibrillation.

Adherence to oral anticoagulation affects outcomes in AF patients at high stroke risk

Literature 29-2-2016 • Yao et al., J Am Heart Assoc. 2016
In patients with atrial fibrillation, adherence to oral anticoagulation for stroke prevention was modestly improved by the use of NOACs, which impacts mainly the outcomes of high-risk patients.

Next step on the way to approval of first antidote to anticoagulant effect of NOAC

News 28-9-2015
Following accelerated assessment, EMAs CHMP recommends granting a marketing authorisation for idarucizumab, a reversal agent for dabigatran, given its potential to respond to an unmet medical need.

Safety and efficacy of dabigatran confirmed in elderly real-world atrial fibrillation patients

Literature 4-11-2014 • Graham DJ et al., Circulation. 2014
FDA analysis of over 67.000 Medicare patients with non-valvular AF receiving dabigatran confirms efficacy- and safety profile as observed in RE-LY trial, as compared with warfarin.

A more nuanced view from the clinic on the critical BMJ publications about dabigatran

News 19-8-2014
Dr. Michiel Coppens (vascular medicine, Academic Medical Center, Amsterdam, NL) shares his views on the critical publications in BMJ about the safety of using dabigatran.

BMJ criticises safety and use of dabigatran

News 18-8-2014
British Medical Journal writes that information has been withheld about the importance of monitoring plasma levels of dabigatran. We summarise the critic and the producer's response.

European approval for dabigatran for treatment of deep venous trombosis and pulmonary embolism

News 22-6-2014
The European Commission approved dabigatran etexilate for treatment of deep venous thrombosis and pulmonary embolism, and prevention of recurrent DVT and PE.

European label of dabigatran use gives better efficacy and safety

Literature 18-12-2013 • Lip et al. Thromb Haemost. 2013
The preferred dose of dabigatran is 150 mg bid, but in contrast with the FDA, the EU label recommends 110 mg bid for patients with high risk of bleeding, which proves to be a relevant alternative.

Efficacy of dabigatran vs. warfarin in stroke prevention maintained with renal dysfunction

Literature 16-12-2013 • Hijazi et al., Circulation. Dec 2013
Generally, renal function did not affect the relative safety of dabigatran over warfarin, although estimation of eGFR with CKD-EPI showed a larger reduction of major bleeding risk when eGFR > 80 ml/min.

Favourable risk/benefit ratio of NOACs over warfarin in meta-analysis of large trials

Literature 9-12-2013 • Ruff et al., The Lancet 2013
Combined data from RE-LY, ROCKET-AF, ARISTOTLE and ENGAGE AF-TIMI 48 showed that NOACs safely reduce stroke and systemic embolism in comparison with warfarin, in atrial fibrillation.

Antithrombotic therapy only modestly reduces mortality in AF, thus management of CV comorbidities may be more effective

Literature 25-9-2013 • Marijon E, Le Heuzey JY, Connolly S, et al.
RE-LY: Dabigatran reduced vascular, but not other causes of mortality as opposed to warfarin. However important, anti- thrombotic treatment only modestly reduces mortality.

Novel use for new anticoagulant dabigatran

Literature 22-2-2013 • Schulman S, Kearon O, Kakkar AK, et al
New information about the risks and benefits of extended prophylaxis with dabigatran in patients who have had venous thromboembolism (VTE)

Dabigatran summary. Meta-analysis of noninferiority randomized controlled trials

News 18-4-2012
This analysis is driven primarily by the RE-LY trial,(1) which contributes 75% of the weight to the overall effect size. It is noteworthy that the results are rendered non-significant (OR 1.16; 95%CI 0.69 to 1.94) when RE-LY is excluded from the analysis.

Upcoming meetings

EPCCS Council Meeting December 6-7, 2017, Stratford Upon Avon, United Kingdom
10th EPCCS Annual CV Summit for Primary care March 15-16, 2018, Malaga, Spain
All upcoming meetings...

Meeting reports & resources

EPCCS 2017 Report of the Cardiovascular Summit held in Dublin, Ireland
EPCCS Guidance Documents Evidence- and meeting-based guidance for primary care
EPCCS 2015 Report of 8th Annual EPCCS meeting held in Prague.
EPCCS 2014 Report of 7th Annual EPCCS meeting held in Brussels.
All meeting reports...